The effect of activation and over-expression of the nuclear receptor PPARβ/δ in human MDA-MB-231 (ER carcinogenesis. These new cell-based models will be invaluable tools for delineating the role of PPARβ/δ in breast cancer and evaluating the effects of PPARβ/δ agonists.
Introduction
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) belongs to the PPAR family of nuclear hormone receptors, which regulate a variety of biological processes, including cell differentiation, cell proliferation, lipid accumulation, and glucose and fatty acid metabolism (1) (2) (3) (4) . Thus, PPARs also influence the development of human diseases, such as diabetes and cancers. PPARβ/δ primarily acts as a transcription factor through dynamic interactions with chromatin with multiple levels of regulation including, the expression level of the receptor, the expression level of co-effectors proteins, the presence of endogenous/exogenous ligands, and the availability of binding sites on chromatin containing target genes and regulatory regions that are modulated through these interactions (5) . However, PPARβ/δ can also directly interact with other transcription factors such as the p65 subunit of NF-kB and repress gene expression; an event associated with its known anti-inflammatory functions (reviewed in (1, 4, 6) ).
Despite the large body of evidence that PPARβ/δ is a protein expressed at very high levels in the skin, intestine and liver (7) , has known potent anti-inflammatory activities (8) , and is required for many important physiological processes (9) , the role of PPARβ/δ in carcinogenesis remains controversial. For example, some studies indicate that activating PPARβ/δ promotes tumorigenesis whereas antagonizing PPARβ/δ inhibits tumorigenesis, for multiple types of cancer (reviewed in (1, 4, 6) ). In contrast, other studies show that activating PPARβ/δ inhibits tumorigenesis, while antagonizing PPARβ/δ promotes or has no effect on tumorigenesis, for multiple types of cancer (reviewed in (1, 4, 6) ).
Thus, controversy exists in the literature indicating that expression and/or activating PPARβ/δ either promotes or inhibits breast cancer based on in vitro and in vivo models. For example, the estrogen receptor-positive (ER + ), MCF7 cell line cultured in vitro with a PPARβ/δ ligand exhibited enhanced cell proliferation and when PPARβ/δ was over-expressed in the same cell line, ligand activation of PPARβ/δ caused an even greater increase in average cell proliferation (10) . Interestingly, the estrogen receptornegative (ER -), MDA-MB-231 cell line did not exhibit any change in cell proliferation following treatment with PPARβ/δ ligands. This may suggest that this effect was in part dependent on the presence of a functional ER (10) . In contrast, another study showed that increased expression of PPARβ/δ was associated with terminal differentiation of MCF7 cells (11) , an effect that is known to coincide with their withdrawal from the cell cycle (12) . The latter study is also consistent with another study that found inhibition of cell proliferation following ligand activation of PPARβ/δ in MCF7 cells (13) . Interestingly, the difference between results from the above studies and those observed by Stephen and colleagues (10) was not due to differences in the ligands used or the presence or lack of serum. In addition, antagonizing PPARβ/δ with GSK3787 had no effect on MCF7 cell proliferation (14) . In vivo analysis examining the effect of PPARβ/δ activation has also led to results that are difficult to interpret. For example, cyclooxygenase-2 (COX2)-null crossed with Pparβ/δ-null mice exhibit reduced tumorigenicity as compared to controls, but tumor multiplicity was not measured (15) . This study suggests that PPARβ/δ is required for mammary tumorigenesis in the Cox2-null transgenic mouse line.
This observation is consistent with results observed after activating PPARβ/δ by low dose GW501516 in FVB mice co-treated with medroxyprogesterone acetate and 7,12-dimethylbenz[a]anthracene (DMBA) where increased mammary tumorigenesis was observed (16) . Unfortunately, tumor multiplicity was again not reported. Most recently, analysis of a single clonal line of transgenic mice over-expressing PPARβ/δ suggested that this receptor can promote mammary tumorigenesis in FVB mice (17) . In contrast to these in vivo results, ex vivo analysis showed dose-dependent decrease in clonogenicity in C20 mouse mammary gland cancer cells in response to ligand activation of PPARβ/δ (18) . Collectively, these studies demonstrate the large variation and difficulty in understanding the role of PPARβ/δ in breast cancer and illustrate the need for additional models to dissect the signaling components or co-factors of this nuclear receptor.
The present study describes the creation and characterizations of two stable human breast cancer cell lines over-expressing PPARβ/δ, the ER -, MDA-MB-231-hPPARβ/δ and ER + , MCF7-hPPARβ/δ cell lines. These cell lines were used to examine the effects of over-expression and/or ligand-mediated activation of PPARβ/δ on cell proliferation, cell cycle, apoptosis, clonogenicity and tumorigenicity using both in vitro, ex vivo and in vivo approaches. 
Materials and Methods

Cell lines
The human breast cancer cell line MDA-MD-231 and MCF7 were obtained from American Type Culture Collection (ATCC, Manassas, VA). The cell lines were tested for authenticity in October 2010 using Short-Tandem Repeat Analysis (IDEXX-RADIL, Columbia, MO). The alleles for 9 different markers were determined and confirmed to be of human origin and non-mammalian inter-species contamination was detected. The PPARβ/δ were generated using the MigR1 retroviral vector that uses a mouse stem cell virus promoter to drive expression of PPARβ/δ, followed by an internal ribosome entry site (IRES) and a sequence encoding enhanced green fluorescent protein (eGFP) (19) as previously described (20, 21) . This vector allows for expression of a protein of interest and/or eGFP (the latter served as a control), which facilitates identification and sorting of cells that have stably integrated the MigR1 retroviral vector as previously described (20, 21) .
Western blotting
Soluble protein lysates were prepared as previously described (20) . Thirty micrograms of protein per independent sample was resolved using SDS-polyacrylamide gels (10 or 12%) and transferred to PVDF membranes using an electroblotting method. Hybridization signals for specific proteins were normalized to that of LDH or β-ACTIN.
Quantitative real-time polymerase chain reaction (qPCR)
qPCR was used to measure the PPARβ/δ target gene angiopoietin-like protein 4 (ANGPTL4) mRNA expression as previously described (22) . Each assay included a standard curve and a non-template control performed in triplicate. The relative mRNA level of ANGPTL4 was normalized to the relative mRNA level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Cell proliferation assay
To determine the effect of over-expression and/or ligand activation of PPARβ/δ on cell proliferation, the xCELLigence system (Roche, Indianapolis, IN) was used as previously described (14) . Cells were plated on 60 mm culture dishes (800 cells/plate) and cultured in medium with or without GW0742 for 12 days to assess clonogenicity as previously described (18) . The plating efficiency and surviving fraction were calculated as previously described (18) .
Ectopic xenografts
Six-week-old female immunodeficient athymic nude (nu/nu) mice ( All in vitro experimental groups were performed in triplicate and repeated using three independent samples of cells. The xenograft studies were performed twice using a total of 10 mice per treatment group. The data were analyzed for statistical significance using analysis of variance followed by the post-hoc Tukey test. Statistical significance was considered when P ≤ 0.05. Values are presented as the mean ± S.E.M.. (Fig. 1A) . Similarly, eGFP was expressed in both MDA-MB-231 and MCF7 cells over-expressing hPPARβ/δ (Fig. 1A) . Increased expression of PPARβ/δ was confirmed by western blot analysis in both MDA-MB-231-hPPARβ/δ and MCF7-hPPARβ/δ cells by 5-fold and ~8-fold, respectively ( (Fig. 1C) .
The lack of a statistically significant increase in ANGPTL4 mRNA in MCF7 and MCF7-MigR1 cells by ligand activation of PPARβ/δ could be due to the fact that expression of PPARβ/δ was not detectable in MCF7 cells compared to low but measureable expression of MDA-MB-231 cells (Fig. 1B) . Fig. 2A and B) . Further, the ligand activation did not influence staurosporine-induced PARP cleavage between any of the MDA-MD-231 cell lines (Supplementary Fig. 2C ). A similar lack of effect was observed in MCF7, MCF7-MigR1 or MCF7-hPPARβ/δ cell lines ( Supplementary Fig. 2A, B and C Fig. 3B ). (Fig. 3A and B) . While ligand activation of PPARβ/δ had no effect on the relative clonogenicity of either MDA-MB-231 or MCF7 cells, inhibition of clonogenicity was observed in MDA-MD-231-MigR1 cells treated with 10 µM GW0742 as compared to controls (Fig. 3C) . Moreover, ligand activation of PPARβ/δ more markedly inhibited clonogenicity in MDA-MD-231-hPPARβ/δ between 0.1 and 10 µM GW0742 as compared to controls (Fig. 3C) . Ligand activation of PPARβ/δ had no effect on the relative clonogenicity of MCF7-MigR1 cells but was inhibited with 1 µM GW0742 in MCF7-hPPARβ/δ cells as compared to controls (Fig. 3D) . Over-expression of PPARβ/δ markedly reduced average tumor volume in both MDA-MD-231 (60%) and MCF7 (20%) xenografts as compared to control MDA-MD-231-MigR1 or MCF7-MigR1 xenografts (Fig. 4A , B, C and D, Supplementary Fig. 4A and B). Ligand activation of PPARβ/δ caused even further reduction in average tumor volume of MDA-MD-231-MigR1 (50%), MDA-MD-231-hPPARβ/δ (90%), MCF7-MigR1 (60%) and MCF7-hPPARβ/δ (80%) xenografts as compared to controls, and this effect was more pronounced in the MDA-MD-231-hPPARβ/δ and MCF7-hPPARβ/δ xenografts compared to their respective controls (Fig. 4A , B, C and D, Supplementary Fig. 4A and B). These changes were reflected by similar changes in relative tumor weight ( Fig. 4E and F). Expression of PCNA was also decreased by ligand activation of PPARβ/δ in MDA-MD-231-hPPARβ/δ xenografts as compared to controls; an effect not found in similarly treated MCF7-hPPARβ/δ xenografts ( Fig. 5A and B) . By contrast, expression of p65 was higher in ligand treated MCF7-hPPARβ/δ xenografts compared to controls and this effect was not found in similarly treated MDA-MB-231-hPPARβ/δ xenografts ( Fig. 5A and B) . Increased expression of ANGPTL4 mRNA confirmed effective activation of PPARβ/δ in the xenografts following treatment with GW0742 ( Fig. 4G and   H ). Histopathological analysis revealed that the necrotic index was greatest in xenografts from ligand-treated MDA-MD-231-hPPARβ/δ xenografts ( Supplementary Fig.   4C ), and interestingly, ligand activation of PPARβ/δ caused an increase in the total necrotic region of xenografts from control MDA-MD-231-MigR1 cells compared to control (Supplementary Fig. 4D ). Additionally, the percentage of necrotic area was Fig. 4E ). These changes in necrosis were not observed in xenografts from MCF7 cells. Thus, despite the increased expression of PPARβ/δ in two human breast cancer cell line-derived tumors, the ratio of FABP5:CRABP-II (Fig. 5A and B Coulter counting and examined cell growth over time (13) , while the present study used real-time assessment of cell proliferation. By contrast, Stephen and colleagues used an enzyme-linked assay that could be influenced by the induction of mitochondrial dehydrogenase enzymes, which are known to be induced by PPARβ/δ ligands (24).
Influence of over-expressed
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Thus, it remains possible that differences in the relative level of PPARβ/δ expression and/or the approach used to assess cell proliferation could explain the differences observed between these studies. 4, 6) ). This suggests that the higher expression of p65 could be the result of its stabilization through its increased binding with PPARβ/δ and the inhibition of xenograft growth may be due to reduced p65-dependent pro-inflammatory signaling. Further studies are needed to examine this hypothesis.
Over-expression and/or ligand activation of PPARβ/δ had no influence on either staurosporine or UVB-induced apoptosis. Previous studies by others have suggested that PPARβ/δ promotes anti-apoptotic signaling through a variety of mechanisms (reviewed in (4, 6) ). One hypotheses is that FABP5 can deliver ligands directly to PPARβ/δ and promote anti-apoptotic activity; this has been suggested in a breast cancer model (23) . However, results from the present studies and other work have shown that despite increasing the intracellular concentration of PPARβ/δ and in the presence of FABP5, FABP5 does not function to deliver ligands to PPARβ/δ, and activating PPARβ/δ does not result in anti-apoptotic activities (20) (21) (22) 31) . These findings re-emphasize the need for further studies examining the role of PPARβ/δ in apoptosis to clarify these disparities. 
